İbrahim Gündüz

Dr. İbrahim Gündüz

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2020 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
İbrahim Gündüzİbrahim Gündüz
İbrahim Gündüz
IBIbrahim Batmaz
Ibrahim Batmaz
TBTurgut Bozan
Turgut Bozan
AEAysun Ekinci
Aysun Ekinci
RÇRemzi Çevik
Remzi Çevik

15 January 2020 in Human Movement Science
Verified
Journal Article
Closed access
POPelin Oktayoglu
Pelin Oktayoglu
AAAbdullah Acar
Abdullah Acar
İbrahim Gündüzİbrahim Gündüz
İbrahim Gündüz
MCMehmet Caglayan
Mehmet Caglayan
MAMuhittin Cenk Akbostanci
Muhittin Cenk Akbostanci

15 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JKJehat KILIÇ
Jehat KILIÇ
GYGülşah Yamancan
Gülşah Yamancan
YDYusuf Doğan
Yusuf Doğan
SŞSümeyye Şahin
Sümeyye Şahin
İbrahim Gündüzİbrahim Gündüz
İbrahim Gündüz
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
Background: Behçet’s disease is a multisystem inflammatory disorder with a variable clinical course. This study evaluated the association between inflammatory indices, clinical involvement, and mortality. Methods: This retrospective study included 444 patients with BD. Clinical characteristics and laboratory data were systematically retrieved from electronic medical record system. Inflammatory indices (NLR, PLR, SII) were calculated to reflect systemic inflammation. In addition, CRP-based composite indices (IBI-NLR and IBI-SII) were derived to integrate cellular and acute-phase inflammatory responses. Disease manifestations, major organ involvement, comorbidities, and mortality were recorded to comprehensively assess disease burden and clinical outcomes. Results: In multivariable analysis, vascular involvement was associated with increased ESR level (OR = 1.013, 95% CI: 1.002–1.024, p = 0.018), and male sex (OR = 3.22, 95% CI: 1.83–5.67, p < 0.001;). ROC analysis showed the highest discriminatory performance for vascular involvement, with IBI-NLR (AUC = 0.624, p < 0.001), IBI-SII (AUC = 0.609, p = 0.001) and NLR (AUC = 0.597, p = 0.004). Moreover, NLR (AUC = 0.571, p = 0.017), IBI-NLR (AUC = 0.576, p = 0.010), and IBI-SII (AUC = 0.562, p = 0.036) had modest discrimination for major organ involvement. In contrast, inflammatory indexes were not predictive for mortality (p > 0.05 for all). Mortality was independently associated with higher creatinine (OR = 1.086, p = 0.048), higher ESR (OR = 1.023, p = 0.046), and lower uric acid levels (OR = 0.454, p = 0.002). Conclusions: Inflammatory indices may not predict mortality in BD but can help identify vascular and major organ involvement. Male sex and ESR level are associated more severe disease, while mortality is associated with renal dysfunction and systemic inflammation in BD.

23 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
BÖBurak Öz
Burak Öz
İbrahim Gündüzİbrahim Gündüz
İbrahim Gündüz
GYGulsah Yamancan
Gulsah Yamancan
YDYusuf Doğan
Yusuf Doğan
RARamazan Fazil Akkoc
Ramazan Fazil Akkoc
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
Background/Objectives: Isthmin-1 (ISM1) is a secreted protein involved in immune regulation, inflammation, and angiogenesis. Although ISM1 has been implicated in chronic inflammatory conditions, its clinical relevance in rheumatoid arthritis (RA) remains unknown. This study aimed to evaluate serum ISM1 levels in RA patients and assess their associations with disease activity, autoantibody status, and inflammatory markers. Methods: This cross-sectional study included 90 RA patients fulfilling the 2010 ACR/EULAR criteria and 30 age- and sex-matched healthy controls. Serum ISM1 concentrations were measured using ELISA. Disease activity was assessed using DAS28-CRP and DAS28-ESR. Statistical analyses included group comparisons, correlation testing, multivariate linear regression, and ROC curve analysis to evaluate the predictive performance of ISM1 for remission or low disease activity. Results: Serum ISM1 levels were significantly lower in RA patients than in controls (454 ± 378 vs. 972 ± 809 ng/L, p < 0.001). ISM1 concentrations were inversely correlated with CRP, ESR, and both DAS28 indices. Multivariate regression confirmed independent associations between lower ISM1 concentrations and higher disease activity. ISM1 levels were significantly reduced in RF- and anti-CCP-positive patients, as well as in treatment-naïve early RA. ROC analysis identified a cut-off value of 673.73 ng/L for predicting remission or low disease activity, with an AUC of 0.713 (95% CI: 0.596–0.820), 100% specificity, and 38.9% sensitivity. Conclusions: This study is the first to demonstrate that serum ISM1 is independently associated with disease activity and autoantibody positivity in RA. High ISM1 levels may serve as a specific indicator of clinical remission or low disease activity, supporting its potential as a non-invasive biomarker for disease monitoring.

12 March 2024 in Rheumatology Quarterly
Verified
Journal Article
Closed access
MAMESUDE SEDA AYDOĞDU
MESUDE SEDA AYDOĞDU
AKAhmet Karataş
Ahmet Karataş
HAHAKAN ARTAS
HAKAN ARTAS
İbrahim Gündüzİbrahim Gündüz
İbrahim Gündüz
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
Aim:Idiopathic granulomatous mastitis (IGM) is a rare chronic inflammatory breast disease. Histopathology is characterized by non-caseating granulomas. Although oral contraceptive use, pregnancy, breastfeeding history, high prolactin levels, smoking, and chemical irritation have been blamed for its etiology, it has not been fully elucidated. We studied the responses obtained using intralesional (IL) steroid application in addition to conventional treatments in patients with IGM referred to the rheumatology and radiology departments of Fırat University Research Hospital. Material and Methods:Seventy-six female patients diagnosed with IGM who were followed between January 2021 and May 2023 were included in the study. The pathologies of the patients, whose average age was 36.5±6.8 years, were compatible with IGM. In terms of differential diagnoses, other conditions that could cause granulomatous mastitis were excluded. The data obtained were analyzed with appropriate statistical methods using statistical package for social sciences (SPSS) for Windows 25. Results:Remission was achieved in 55.3% of patients (42 patients). While remission was observed in 61.6% of the patients who received IL steroids, remission was achieved in only 23.1% of the patients who did not receive IL steroids, and this rate was found to be statistically significant (p=0.010). There was no statistically significant difference between the treatments received by patients who achieved remission and those received by patients whose treatment continued (p>0.05). Conclusion:In our study, the treatments received by patients who were and were not administered IL steroids were similar, but a significant difference was observed in patients who were administered IL steroids in terms of achieving remission. This suggested that IL steroid administration would have a positive contribution to the treatment response.

16 January 2026 in Archives of Rheumatology
Verified
Journal Article
Open access
PDF file
MÇMehmet Çağlayan
Mehmet Çağlayan
POPelin Oktayoglu
Pelin Oktayoglu
YCYusuf Celik
Yusuf Celik
İbrahim Gündüzİbrahim Gündüz
İbrahim Gündüz
ZSZeynep Işık Sula
Zeynep Işık Sula
İsmail YILDIZİsmail YILDIZ
İsmail YILDIZ
Background/Aims: Fibromyalgia (FM) is a chronic pain condition in which patients experience diffuse musculoskeletal discomfort accompanied by marked fatigue, non-restorative sleep patterns, and cognitive complaints. Individuals with FM exhibit elevated inflammatory cytokines. The aim was to investigate the prevalence of FM in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) and to evaluate the effects of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) on FM. Materials and Methods: Patients were enrolled in the study, including spondyloarthritis and RA patients. Disease activity in RA patients was assessed using the Disease Activity Score–28 scores. For SpA patients, the Bath Ankylosing Spondylitis Disease Activity Index and the Bath Ankylosing Spondylitis Metrology Index were used to evaluate disease activity and structural damage. Patients were evaluated for FM according to the 1990 American College of Rheumatology classification criteria. The Fibromyalgia Impact Questionnaire was administered for FM severity. Results: There was no significant difference in the prevalence of FM between the RA and SpA groups (P = .942). The prevalence of FM was significantly higher among patients not receiving b/tsDMARDs compared to those who were (P = .033). In the SpA subgroup, no significant difference in FM prevalence was observed between patients using and not using b/ tsDMARDs (P = .314). However, in the RA subgroup, FM prevalence was significantly higher among patients not receiving b/tsDMARDs (P = .030). Conclusion: The findings suggest that the use of b/tsDMARDs appears to be associated with a reduced prevalence of FM among patients with RA. It is believed that this study provides a window for future studies. Cite this article as: Caglayan M, Oktayoglu P, Celik Y, et al. Assessment of the concomitance of fibromyalgia in patients with axial spondyloarthritis and rheumatoid arthritis. ArchRheumatol. 2026;41(1):72-80.